Jump to the main text


Hitachi America, Ltd.

Proton Beam Therapy

Proton Beam Therapy (PBT) is an emerging form of radiation therapy that can maximize radiation doses to the target tumor, while sparing adjacent healthy tissues. PBT has demonstrated efficacy for a number of relatively rare cancers - providing high rates of tumor control and survival, while reducing radiation - related side effects. Due to the physics of proton particles, proton enter the body, deposit most of their energy in the final portion of their trajectory and stop (this is known as the Bragg peak). There is no exit dose. As a result, exposure of normal tissue to radiation is minimized, and higher radiation dose can be administered to the tumor area.

Hitachi has over 20 years of proven particle therapy technology experience, consisting of designing, manufacturing and implementing key particle accelerating components and technologies at various international recognized centers of excellence including:

  • National Institute of Radiological Science (NIRS) at Chiba, JAPAN
  • National Cancer Center (NCC) Hospital East at Kashiwa, JAPAN
  • Wakasa Wan Energy Research Center Wakasa Bay, JAPAN
  • The Proton Medical Research Center, University of Tsukuba, JAPAN
  • MD Anderson Cancer Center in Houston, Texas, USA
  • Heidelberg Ion-Beam Therapy Centre, Heidelberg University, Germany (RF Accelerator Cavities)
  • Nagoya City Quality Life 21 Jouhoku,  JAPAN
  • Hokkaido University,  JAPAN
  • Mayo Clinic Rochester, MN / Phoenix, AZ  USA
  • St. Jude Children’s Research Hospital, Memphis, TN  USA

In May 2006, MD Anderson Cancer Center in Houston, Texas has started treating patients using Hitachi Proton Beam Therapy System PROBEAT™. The system has both passive and discrete spot scanning treatment rooms and Hitachi has obtained FDA clearance for booth passive and discrete spot scanning technology.

Hitachi continues to define new technological limits by developing new analysis and fabrication techniques. Hitachi has proved its capability by developing and obtaining FDA clearance for discrete spot scanning technology at MD Anderson Cancer Center first in the world. In the future, Hitachi intends to continue to stay at the technology’s cutting edge of charged particle cancer therapy by enhancing the capabilities of the synchrotron accelerator for delivery of increasingly heavier particles such as carbon.

MD Anderson Cancer Center


Please email protonbeam@hal.hitachi.com for information about Proton Beam Therapy.